Regulatory overview of biosimilars in Europe
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 3
Abstract
A biosimilar is a biological medicine similar, but not identical, to an already registered reference bio therapeutic product in terms of quality, safety, and efficacy. These drugs are also called as biosimilar products„, follow-on protein products‟ and subsequent-entry biologics„. The EU has pioneered the regulation of biosimilar medicines by establishing a solid framework for their approval and by shaping biosimilar development globally. Since the EU approved the first biosimilar in 2006, healthcare professionals have gained increasing experience with their use. Today, biosimilars are an integral part of the effective biological therapies available in the EU, supported by adequate safeguards protecting patient safety. In Europe, in 2001, legislation concerning biosimilar was codified as Directive 2001/83/EC to create a new marketing authorization procedure for similar biological medicinal products and also Committee for Medicinal Products for Human Use (CHMP) of the EMA is concern with these biosimilar products. The aim of biosimilars development is to demonstrate bio similarity - high similarity in terms of structure, biological activity and efficacy, safety and immunogenicity profile. Safety of biosimilars is monitored through pharmacovigilance activities, in the same way as for any other medicine. Biosimilars can offer advantages to EU healthcare systems, as it is expected to improve patients‟ access to safe and effective biological medicines with proven quality.
Authors and Affiliations
Shailaja Pashikanti, Jyothi Sri Durga V, Sowmya A. N. V. L
Keywords
Related Articles
- EP ID EP426949
- DOI 10.22270/ijdra.v6i3.270
- Views 113
- Downloads 0
Drug approval process in India and Europe
Every time a new drug is developed it requires a great amount of research work in manufacturing, Pre- clinical Science, Controls, Chemistry & Clinical trials. Regulatory agencies have Drug Reviewers who has the responsib...
A Comprehensive and Comparative study of qualification process for Drug Development tools in US, Europe, Japan and India
Drug Development Tools are methods, materials, or measures that have the potential to facilitate drug development. USFDA has specified three major drug development tools and has also given the guidelines recommending the...
PREPARATION & COMPILATION OF ACTD DOSSIER (PART II QUALITY)
ACTD is a critical document for drug substance and produces registration in ASEAN region. The document is essentially divided into 4 parts. Each part provides information under specific head. Out of all the parts, the pa...
INTERNATIONAL CONFERENCE ON HARMONISATION: AN OVERVIEW
The International Conference on Harmonisation (ICH) is a project that makes together the regulatory bodies of Europe, Japan and the United States and professionals from the pharmaceutical domain in the three areas to dis...
PHARMACY PROFESSION IN GUJARAT: AN OVERVIEW
Pharmacy is the health profession that links the health science with chemical science and it is charged with ensuring the safe and effective use of pharmaceutical drugs. Gujarat has been one of the pioneer States in Indi...